Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Innovation and research

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

A vaccine platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ vaccine has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics – Q2 2024 Financial Results – presentation

Read More
21 August 2024

Nykode Therapeutics reports Q2 2024 Financial Results

Read More
21 August 2024

Nykode Therapeutics Announces Strategic Repositioning of VB10.16 to Focus ...

Read More
21 August 2024

Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized ...

Read More
14 August 2024

Nykode Therapeutics – invitation to Q2 2024 financial results ...

Read More
01 August 2024

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform ...

Read More
20 June 2024

Nykode Therapeutics – presentation from ABGSC Seminar on Autoimmunity, ...

Read More
11 June 2024

Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

Read More
11 June 2024

Nykode Therapeutics – Q1 2024 Financial Results – presentation

Read More
14 May 2024